Amicus Therapeutics, Inc. (FOLD)
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Investigation
02/19/2021
Initial Lawsuit
02/19/2021
Lawsuit Progression
12/29/2021
Investigation regarding Immunovant’s recent voluntarily pause dosing in its clinical trial ASCEND GO-2 of IMVT-1401 for patients with thyroid eye disease (TED) following a signal of elevated total cholesterol and low-density lipoprotein (LDL) levels.
02/02/2021
Immunovant reported a physiological signal of high cholesterol and LDL levels in IMVT-1401 patients in ASCEND GO-2 trial in TED, and decided to voluntarily suspend the dosing.
Stock Impact
Close | Previous close | Price variation | Percentage variation |
---|---|---|---|
$25.08 | $43.3 | $-18.22 | -42.08% |
Plaintiff brings this securities class action on behalf of a class consisting of all persons and entities other than Defendants that purchased or otherwise acquired Immunovant securities between October 2, 2019 and February 1, 2021, both dates inclusive.
According to the complaint, defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the company’s business, operations, and prospects. Specifically, defendants allegedly failed to disclose to investors that:
(i) Health Sciences Acquisitions Corporation (HSAC) had performed inadequate due diligence into Legacy Immunovant prior to the Merger, and/or ignored or failed to disclose safety issues associated with IMVT-1401;
(ii) IMVT-1401 was less safe than the Company had led investors to believe, particularly with respect to treating thyroid eye disease (TED) and warm autoimmune hemolytic anemia (WAIHA);
(iii) the foregoing foreseeably diminished IMVT-1401’s prospects for regulatory approval, commercial viability, and profitability; and
(iv) as a result, the Company’s public statements were materially false and misleading at all relevant times.
12/29/2021
The court issued an order appointing the lead plaintiff and lead counsel.
02/01/2022
This is a federal securities class action on behalf of a class consisting of all persons and entities other than defendants that purchased or otherwise acquired Immunovant securities in or traceable to the company’s follow-on public offering of securities on September 3, 2020, as well as purchasers of the company’s securities between October 2, 2019 and February 1, 2021, inclusive.
Operative complaint
Whether directors and officers of Amicus Therapeutics, Inc. (FOLD) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Inari Medical, Inc. (NARI) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of Payoneer Global Inc. (PAYO) breached their fiduciary duties to the company and its shareholders.
Confidential investigation: officers & directors’ potential breach of fiduciary duties to investors.
Whether directors and officers of Builders FirstSource, Inc. (BLDR) breached their fiduciary duties to the company and its shareholders.
Whether directors and officers of LegalZoom.com, Inc. (LZ) breached their fiduciary duties to the company and its shareholders.